Refractory Hematologic Cancers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gimv : ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023 -October 19, 2023 at 02:27 am EDT

Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and encouraging clinical activity for ICT01 monotherapy in relapsed/refractory.

Institut paoli calmettesSylvain garciazEuropean society for medical oncologyDepartment of hematologyImcheck therapeuticsEuropean societyMedical oncologyRefractory hematologic cancersAcute myeloid leukemia

Correction: ImCheck to Present New Positive Data on ICT01

ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of.

Institut paoli calmettesMarseille immunopolePaul frohnaPierre peterlinKatrien lemmensEmmanuel valentinPatrick bruneGretchen schweitzerSylvain garciazMarseille universityEuropean society for medical oncologyDepartment of hematologyTrophic communicationsPresent new positive dataHematological cancersImcheck therapeutics

ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023

ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Katrien lemmensPaul frohnaInstitut paoli calmettesMarseille immunopoleGretchen schweitzerPatrick bruneEmmanuel valentinSylvain garciazPierre peterlinEuropean society for medical oncologyTrophic communicationsMarseille universityDepartment of hematologyPresent new positive dataHematological cancersImcheck therapeutics